186 related articles for article (PubMed ID: 27056890)
1. Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.
Borland G; Kilbey A; Hay J; Gilroy K; Terry A; Mackay N; Bell M; McDonald A; Mills K; Cameron E; Neil JC
Oncotarget; 2016 Apr; 7(17):22973-87. PubMed ID: 27056890
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic Runx1-Myc axis in p53-deficient thymic lymphoma.
Date Y; Taniuchi I; Ito K
Gene; 2022 Apr; 819():146234. PubMed ID: 35114276
[TBL] [Abstract][Full Text] [Related]
3. Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.
Kilbey A; Terry A; Wotton S; Borland G; Zhang Q; Mackay N; McDonald A; Bell M; Wakelam MJ; Cameron ER; Neil JC
J Cell Biochem; 2017 Jun; 118(6):1432-1441. PubMed ID: 27869314
[TBL] [Abstract][Full Text] [Related]
4. RUNX1 is required for oncogenic
Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
[TBL] [Abstract][Full Text] [Related]
5. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
6. Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.
Hay J; Gilroy K; Huser C; Kilbey A; Mcdonald A; MacCallum A; Holroyd A; Cameron E; Neil JC
J Cell Biochem; 2019 Oct; 120(10):18332-18345. PubMed ID: 31257681
[TBL] [Abstract][Full Text] [Related]
7. p53 and p73 in suppression of Myc-driven lymphomagenesis.
Griesmann H; Schlereth K; Krause M; Samans B; Stiewe T
Int J Cancer; 2009 Jan; 124(2):502-6. PubMed ID: 18942718
[TBL] [Abstract][Full Text] [Related]
8. Bim is a suppressor of Myc-induced mouse B cell leukemia.
Egle A; Harris AW; Bouillet P; Cory S
Proc Natl Acad Sci U S A; 2004 Apr; 101(16):6164-9. PubMed ID: 15079075
[TBL] [Abstract][Full Text] [Related]
9. Runx1 promotes B-cell survival and lymphoma development.
Blyth K; Slater N; Hanlon L; Bell M; Mackay N; Stewart M; Neil JC; Cameron ER
Blood Cells Mol Dis; 2009; 43(1):12-9. PubMed ID: 19269865
[TBL] [Abstract][Full Text] [Related]
10. C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent.
Trudel M; Lanoix J; Barisoni L; Blouin MJ; Desforges M; L'Italien C; D'Agati V
J Exp Med; 1997 Dec; 186(11):1873-84. PubMed ID: 9382886
[TBL] [Abstract][Full Text] [Related]
11. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.
Blyth K; Vaillant F; Hanlon L; Mackay N; Bell M; Jenkins A; Neil JC; Cameron ER
Cancer Res; 2006 Feb; 66(4):2195-201. PubMed ID: 16489021
[TBL] [Abstract][Full Text] [Related]
12. Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells.
Mensink M; Anstee NS; Robati M; Schenk RL; Herold MJ; Cory S; Vandenberg CJ
Cell Death Differ; 2018 Mar; 25(4):797-808. PubMed ID: 29339775
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of the PI3K/AKT and RHO/RAC/PAK signalling pathways in CHK1 inhibitor resistant Eµ-Myc lymphoma cells.
Hunter JE; Campbell AE; Kerridge S; Fraser C; Hannaway NL; Luli S; Ivanova I; Brownridge PJ; Coxhead J; Taylor L; Leary P; Hasoon MSR; Eyers CE; Perkins ND
Biochem J; 2022 Oct; 479(19):2131-2151. PubMed ID: 36240067
[TBL] [Abstract][Full Text] [Related]
14. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Eischen CM; Alt JR; Wang P
Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
[TBL] [Abstract][Full Text] [Related]
15. B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma.
Ruddell A; Harrell MI; Furuya M; Kirschbaum SB; Iritani BM
Neoplasia; 2011 Aug; 13(8):748-57. PubMed ID: 21847366
[TBL] [Abstract][Full Text] [Related]
16. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase.
Shreeram S; Hee WK; Demidov ON; Kek C; Yamaguchi H; Fornace AJ; Anderson CW; Appella E; Bulavin DV
J Exp Med; 2006 Dec; 203(13):2793-9. PubMed ID: 17158963
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the Arf tumor suppressor in Emicro-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis.
Bertwistle D; Sherr CJ
Blood; 2007 Jan; 109(2):792-4. PubMed ID: 16968893
[TBL] [Abstract][Full Text] [Related]
18. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
19. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
[TBL] [Abstract][Full Text] [Related]
20. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.
Kelly GL; Grabow S; Glaser SP; Fitzsimmons L; Aubrey BJ; Okamoto T; Valente LJ; Robati M; Tai L; Fairlie WD; Lee EF; Lindstrom MS; Wiman KG; Huang DC; Bouillet P; Rowe M; Rickinson AB; Herold MJ; Strasser A
Genes Dev; 2014 Jan; 28(1):58-70. PubMed ID: 24395247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
